Author: CannabisNewsWire (CNW)

About CannabisNewsWire CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge. To receive SMS text alerts from CannabisNewsWire, text “CANNABIS” to 21000 (U.S. Mobile Phones Only) For more information please visit https://www.CannabisNewsWire.com Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

420 with CNW — DEA Informs Congress It Has Final Say on Cannabis Scheduling Despite HHS Recommendation

The U.S. Drug Enforcement Agency (DEA) has asserted its ultimate authority in determining the scheduling of cannabis, regardless of the recommendations made by the U.S. Health and Human Services. Michael Miller, the DEA acting chief of the Office of Congressional Affairs, communicated this stance in a letter addressed to Representative Earl Blumenauer, cochair of the Congressional Marijuana Caucus.

The scheduling review process, initiated by President Joseph Biden in October 2022, commenced with a scientific assessment from the HHS. The assessment purportedly advised the DEA to reclassify cannabis from Schedule I to Schedule III of the Controlled Substances Act (CSA). After HHS provided its recommendation in August, the DEA proceeded with its independent review.

The DEA’s response was prompted by an earlier letter from 31 bipartisan legislators, led by Blumenauer, urging the DEA to consider the merits of legalization during the review. The lawmakers expressed concern about the limitations of placing marijuana in Schedule III rather than completely removing it from CSA control. They emphasized the urgency of full descheduling and criticized the outdated scheduling of cannabis, which they deemed incongruent with the public’s sentiment.

In its reply, the DEA refrained from addressing the lawmakers’ arguments and focused on the procedural details of the scheduling review. The timeline for completing the review remains undisclosed, though speculation suggests a conclusion before the November election.

The Congressional Research Service (CRS) suggested that, based on past precedent, the DEA would likely follow HHS’s recommendation. However, the DEA reiterated its final jurisdiction over the CSA, retaining the authority to disregard HHS advice.

Despite the controversy surrounding the rescheduling review, little is known about HHS’s justification for recommending Schedule III. The agency submitted extensive documents to the DEA, but those documents have been released in highly redacted form, offering scant insight into the health agency’s findings on medical benefits, addictive potential or other policy aspects.

The DEA has received input from various stakeholders, including 29 former U.S. attorneys, urging the preservation of Schedule I. Six governors and former DEA heads voiced opposition to HHS’s recommendation, highlighting the complexity of the marijuana policy debate.

Lawmakers and advocates supporting marijuana reform marked the one-year anniversary of Biden’s cannabis pardon and scheduling directive by urging further action. Two GOP senators introduced legislation to prevent federal agencies from rescheduling cannabis without congressional approval.

Simultaneously, a coalition of 14 GOP legislators urged the DEA to reject HHS’s recommendation and maintain the strictest categorization for cannabis under the CSA.

Actors in the marijuana space, such as Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), are eagerly waiting for the decision that the DEA will make on cannabis classification under the CSA.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Biden Again Excludes Serving Military Personnel from Latest Cannabis Pardons

The latest round of pardons for American citizens with federal simple possession, attempted possession and use of marijuana by President Joe Biden have excluded serving military personnel again. First issued on Oct. 6, 2022, the presidential proclamation pardoned several federal simple cannabis possession offenses before another proclamation extended the number of pardoned offenses on Dec. 22, 2023.

While the first round of pardons was lauded as a major step toward fixing the damage caused by decades of cannabis prohibition, many advocates noted that the pardons were severely limited in scope and did not provide relief to many drug-war victims. The pardons only covered around several thousand people who had been convicted of federal cannabis possession offenses but left out military service members, noncitizens and people convicted of selling cannabis.

President Biden extended the proclamation last December to include individuals who were charged with cannabis possession offenses on federal properties. In a statement released shortly after the proclamation, Biden said that cannabis use and possession offenses have prevented people from accessing employment, housing and educational opportunities. He acknowledged that the government’s approach to marijuana had failed and said that it was time to “right these wrongs.” However, the president’s pardons excluded service members with simple-possession and marijuana-use offenses on their records.

An official from the White House confirmed that the December 2023 proclamation does not apply to offenses prosecuted under the Uniform Code of Military Justice. This essentially means that military service members who were charged with cannabis offenses in the past would not qualify for Biden’s latest round of pardons.

Although none of the 2022 and 2023 presidential proclamations resulted in any American being freed from federal prison, the removal of a federal cannabis conviction from an individual’s record can eliminate barriers to housing, education and reliable employment.

If the pardons also covered military service members with cannabis-related convictions, they could change their military discharge status and gain access to certain benefits. Unfortunately, while the president does have the unilateral right to change some punishments under the Manual for Courts-Martial, any major changes to the Uniform Code of Military Justice (USMJ) would have to go through Congress.

The UCMJ currently levies a maximum punishment of two years, forfeiture of pay and dishonorable discharge for marijuana possession.

Florida International University associate professor of law and military justice specialist Eric Carpenter says it isn’t surprising that Biden excluded military service members from this round of pardons. He explained that the use of drugs in the military tends to be more serious than recreational drug use by civilians’ because it can compromise good order and discipline.

The entire marijuana industry, including actors like Verano Holdings Corp. (CSE: VRNO) (OTCQX: VRNOF), will be hoping that ways can also be explored to grant serving military personnel the pardons that civilians can access under the evolving regulatory landscape of cannabis.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

CannabisNewsBreaks – Why Astrotech Corporation (NASDAQ: ASTC) Is ‘One to Watch’

Astrotech (NASDAQ: ASTC ) is an instrumentation company that designs, manufactures and commercializes solutions. These include mass spectrometry, process controls, chemical detectors and medical disease detection. The company is headquartered in Austin, Texas, and owns four subsidiaries: Astrotech Technologies Inc., 1st Detect Corp., AgLAB Inc., and BreathTech Corp. “Between 2016 and 2019, the company secured U.S. patents for its technology and achieved European Union (‘ECAC’) certification for the TRACER 1000(TM), the world’s first mass-spec Explosives Trace Detector (‘ETD’) used in airports worldwide,” a recent article reads. “Astrotech continues to innovate and add to its suite of products, including AgLAB-1000, a process control system, and the BreathTest 1000, a disease detection solution.”

To view the full article, visit https://cnw.fm/8vFUf

About Astrotech

Astrotech is an innovative science and technology company that invents, acquires and commercializes technological innovations while building scalable companies to maximize shareholder value. For more information, please visit www.AstrotechCorp.com.

NOTE TO INVESTORS: The latest news and updates relating to ASTC are available in the company’s newsroom at https://ibn.fm/ASTC

About CannabisNewsWire

CannabisNewsWire (“CNW”) is a specialized communications platform with a focus on cannabis news and the cannabis sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled recognition and brand awareness. CNW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Five Predictions for the Marijuana Industry in 2024

In anticipation of the U. S. Drug Enforcement Administration’s (DEA) upcoming decision on marijuana rescheduling, the cannabis industry braces for what could be the most significant change in U.S. marijuana policy in half a century. The potential rescheduling carries the promise of tax reform, specifically the elimination of Section 280E from the federal tax code. The section has been a financial burden on state-legal marijuana retailers and has repercussions throughout the supply chain.

As we look ahead, here are five predictions for the cannabis industry in the coming year:

Rescheduling marijuana and eventual tax relief

The DEA is likely to propose the rescheduling of cannabis, aligning with the HHS’ recommendation to move the substance from Schedule I to Schedule III of the Controlled Substances Act. This acknowledgment of marijuana’s medical value, influenced by state-provided data, initiates the ongoing administrative review launched by the Biden Administration in October 2022. Legal challenges are likely to follow.

Rescheduling would bring tax relief as Section 280E’s constraints on federal tax deductions for state-legal marijuana businesses would cease. This change holds the potential to inject more financial strength into the $34 billion U.S. cannabis industry. Some businesses are already seeking refunds, setting the stage for potential shifts in the industry’s financial landscape.

Federal progress in limbo

While banking reform legislation gained traction in 2023, the chances of its passage in the current Congress are uncertain. A mere 13% of senior congressional aides anticipate success, signaling potential deadlock. The hope for federal Farm Bill amendments addressing hemp-derived competition persists, but state-level hurdles might complicate matters.

Next legalization frontiers

Pennsylvania and Florida emerge as potential candidates for the next states to legalize cannabis. Ohio’s recent move toward adult-use marijuana suggests a shifting landscape, prompting attention to Florida’s 2024 ballot and Pennsylvania’s legislative developments, despite partisan divisions.

Combating the illicit market

States are gearing up to tackle the burgeoning illicit market, exemplified by New York’s struggle with unlicensed sellers. While legal retail capacity expands, the effectiveness of new options in redirecting customers away from the illicit market remains uncertain. Regulators face the challenge of balancing enforcement and incentives.

Social-equity challenges

States have been grappling with the implementation of social-equity promises in the legal cannabis industry. New York’s attempts to prioritize small businesses face constitutional challenges, prompting a reevaluation of strategies to ensure equitable participation. The industry is under pressure to address legal challenges from excluded entrepreneurs, necessitating innovative solutions.

As the industry navigates these potential developments, 2024 promises transformative shifts in policy, taxation and societal impact. Enterprises such as Tilray Brands Inc. (NASDAQ: TLRY) (TSX: TLRY) will be looking for any new opportunities that they can leverage to deepen their penetration in jurisdictions with legal cannabis markets.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Lawmakers in Wisconsin Introduce Bill to Decriminalize Marijuana

Wisconsin may be the latest state to pass cannabis reform measures after a bipartisan group of lawmakers formally introduced a proposal to decriminalize cannabis possession in late December. First previewed in early December, the noncommercial and relatively limited reform may garner enough support to advance past Wisconsin’s GOP-controlled legislature.

The marijuana decriminalization measure was introduced by Representatives David Considine, Sylvia Ortiz-Velez and Shae Sortwell alongside Senator Lena Taylor. Assembly Bill 861 would remove criminal penalties such as jail time for cannabis-related offenses, such as simple possession of up to 14 grams of marijuana, and replace criminal charges for cannabis offenses with a $100 civil penalty.

Current Wisconsin law criminalizes cannabis possession and punishes the offense with a maximum of six months in jail and a $1,000 fine.

The proposed decriminalization measure would also eliminate the need for people charged with cannabis possession to appear in court and replace it with a simple $100 fine. Additionally, the decriminalization measure would stop Wisconsin courts from counting cannabis possession convictions that involve up to 28 grams of cannabis. This means Wisconsin residents would never again be charged as repeat offenders for possessing small amounts of marijuana.

The measure also reduced penalties for repeatedly possessing larger amounts of cannabis from three and a half years imprisonment to 90 days. Individuals charged with drug paraphernalia possession will be liable to a $10 civil forfeiture fine down from as much as 30 days in jail and a $500 fine.

According to a censorship memo released by the measure’s sponsors, Wisconsin should not be imprisoning its residents for simply possessing small amounts of cannabis. On average, Wisconsin makes 15,485 arrests for minor cannabis possession and punishes simple possession suspects with up to six months in jail and a maximum $1,000 fine. The proposed measure would also grant law enforcement more flexibility on how they choose to deal with individual cannabis possession cases. This includes deciding whether or not to book and process individuals for simple cannabis possession or simply collecting certain personal information.

The measure would also reduce the liability of employers who choose not to test their employees for THC. However, these workplace testing provisions would not apply to jobs involving security and safety or those overseen by the federal Department of Transportation. The sponsorship memo noted that employers are increasingly choosing to forgo cannabis tests because they can be costly.

Assembly Bill 861 will head to the Assembly Committee on Criminal Justice and Public Safety.

If this reform movement results in the eventual legalization of cannabis, it could lead existing companies such as TerrAscend Corp. (TSX: TSND) (OTCQX: TSNDF) to weigh whether or not to expand their footprints into those new markets.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

CannabisNewsBreaks – Branded Legacy Inc. (BLEG) Acquires All In Extracts LLC

Branded Legacy (OTC: BLEG), (soon to be known as Royal Enterprises Inc.), a burgeoning company in the pharmaceutical biotechnology sector, today announced its strategic acquisition of All In Extracts, a pioneering entity focused on medicinal ethnobotany. The milestone deal amplifies Branded Legacy’s focus on innovation, expansion and collaborative growth within the biotech community. “As soon as I met with the All In team, I knew something great was in the making,” said Branded Legacy CEO David Oswald. “It is a rare enough thing to find a company motivated primarily by the positive impact they can make on society. We are extremely pleased that they saw the same in us. The balance between All In and our subsidiary Royal Biotek is uncanny, from production areas where one is weak and the other is strong, to marketing and branding abilities vs inventory on hand. We even have the perfect balance of equipment in our labs with little to no overlap: their lab is exactly what our next expansion would have been, and vice versa. This is the yin and yang of mergers.”

To view the full press release, visit https://cnw.fm/oaefL

About Branded Legacy Inc.

Branded Legacy is a diversified holdings company focused on the biotech sector. With a commitment to excellence and innovation, Branded Legacy specializes in the development and marketing of cutting-edge products and services. The company’s diverse portfolio includes ventures in biotechnology, digital solutions and wellness products, all aimed at enhancing the quality of life for its customers. Branded Legacy’s strategic approach to growth involves identifying and integrating promising businesses and technologies that align with its mission to deliver sustainable, high-quality products and services. For more information, visit the company’s website at https://BrandedLegacy.com.

About CannabisNewsWire

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

CannabisNewsBreaks – Software Effective Solutions Corp. (SFWJ) Featured in Bell2Bell Podcast

Software Effective Solutions (OTC: SFWJ) (d/b/a MedCana), a global infrastructure and holding company in the cannabis industry, was featured in the latest episode of the Bell2Bell Podcast, a part of IBN’s sustained effort to provide specialized content distribution via widespread syndication channels. Jose Gabriel Diaz, CEO of Software Effective Solutions, joined the program to provide an introduction to MedCana and its business model. “We are a U.S.-based holding company focused on developing infrastructure and cannabis companies around the world. Right now, the focus is primarily on markets outside of the U.S. that have already fully legalized pharmaceutical (and possibly some recreational) cannabis. We’re looking at Switzerland, Germany, Portugal, Spain and most of Europe, as well as Australia, Brazil, Argentina and Uruguay… Our focus, initially, is not going to be into the United States, until there is a 100% guarantee that everything we’re doing is on the legal side,” Diaz said. “The focus is for MedCana to develop these companies that we’ve acquired outside of the U.S. to grow a presence in these international markets. It’s not just cultivation that we’re doing, however. MedCana is an infrastructure company. We also have two other very important companies. One is focused on software to make sure that certifications are being managed by our companies, but not just our companies. These are software products that we will be selling to other companies as we develop them. We also are very focused on infrastructure development of not just cannabis but technology in agriculture… So, it’s developing these markets for the companies that we bought with the licenses. It’s also focusing on infrastructure and software, along with the electronic resource planning and software management of these companies.”

To view the full article, visit https://cnw.fm/wVWk5

About Software Effective Solutions Corp.

Software Effective Solutions/MedCana is a global infrastructure and holding company in the cannabis industry. Currently, MedCana has five companies focused on pharmaceutical cannabis production and one software company focused on managing processes for plant-to-patient operations. The recent acquisition of an irrigation and greenhouse technology company has rounded out MedCana’s portfolio of companies. MedCana’s initial focus is on developing clients and companies in Latin America with an initial focus in Colombia and partnerships with laboratories, research facilities and hospitals throughout the world. For more information, visit the company’s website at www.MedCana.net.

NOTE TO INVESTORS: The latest news and updates relating to SFWJ are available in the company’s newsroom at https://cnw.fm/SFWJ

About CannabisNewsWire

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Federal Lawsuit Challenges Cannabis Advertising Ban in Mississippi

Clarence Cocroft, the owner of Tru Source, a medical marijuana dispensary in Olive Branch, Mississippi, is contending that the ban on medical marijuana advertising in Mississippi is hindering his dispensary’s ability to attract customers. He claims that this prohibition infringes upon his freedom of speech, a claim central to the federal suit filed on Nov. 14, 2023.

The lawsuit targets the regulatory authorities overseeing these restrictions, including the state’s health department, the revenue department, and the state’s bureau of alcohol and beverage control.

While medical cannabis is now legal in Mississippi for persons with qualifying conditions and a medical marijuana card, the state law explicitly forbids dispensary owners and cultivators from promoting marijuana products. To establish a medical marijuana shop, one is required to obtain a dispensary license, obtain a sales tax registration and incur considerable fees. Additionally, patrons must possess a medical marijuana card and be at least 21 years old to enter a dispensary.

Tru Source relies on limited advertising channels, including word of mouth, on-location signage and its website. Cocroft, however, faces restrictions preventing him from promoting the dispensary through other mediums. He highlights that potential customers might remain unaware of the store’s existence unless they happen to pass by.

Represented by the Institute for Justice (IJ), a nationwide libertarian nonprofit law firm, Cocroft’s lawsuit challenges the constitutionality of commercial speech regulations. Katrin Marquez, an attorney for Cocroft, points out how these regulations, viewed through the lens of the First Amendment, impede business growth.

When Tru Source was established, Cocroft invested in billboards in the north of the state for advertising but had to lease the locations to other businesses, such as a casino, capable of legally promoting their products. The case and the resultant media attention have attracted new customers to Tru Source, increasing daily visits from about 15 to 20 patients to 20 to 30 patients picking up medical marijuana products.

Cocroft argues that the ban on advertising not only affects dispensary owners but also impacts cultivators. If dispensaries can’t promote products, their purchasing capacity diminishes, causing financial losses for cultivators. He questions the disparity, noting that industries such as alcohol, medications, casinos and strip clubs can advertise statewide, while marijuana dispensaries face restrictions.

Cocroft highlights the financial burden borne by those invested in Mississippi’s medical marijuana industry, where millions of dollars have been spent in pursuit of helping patients navigate a novel business landscape. In his view, the unequal advertising regulations create a puzzling dichotomy where certain industries can freely advertise, while others, such as Tru Source, face stringent limitations.

It isn’t just cannabis companies in Mississippi that are hamstrung by restrictions on advertising. Other enterprises operating elsewhere, such as SNDL Inc. (NASDAQ: SNDL), are also grappling with limitations on how and where they can advertise their products.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Johns Hopkins Team to Track 10,000 Medical Cannabis Users in Federally Funded Research

Researchers at Johns Hopkins University will be studying the effects of marijuana therapy by closely monitoring 10,000 medical cannabis patients over a five-year period. The study, backed by a generous $10 million grant from the National Institute on Drug Abuse (NIDA), is a collaborative effort with federal researchers and the nonprofit Realm of Caring.

Together, the researchers will amass comprehensive data encompassing delivery methods, product chemical composition, dosage, potential medication interactions and other intricate facets of treatment.

Ryan Vandrey, cocreator of the study and a professor at the Johns Hopkins University School of Medicine, expressed the research team’s objective to comprehend the health impacts of therapeutic cannabis use. The comprehensive study aims to shed light on the diverse landscape of marijuana products, recognize their differences and identify areas of promise. Vandrey emphasized the need to narrow the focus to distinguish helpful products from those that might pose risks, tailoring the research to specific populations and therapeutic purposes.

Despite the increasing volume of cannabis research, federal marijuana laws have posed significant obstacles to scientific exploration. The study recognizes that with more than three-quarters of states legalizing medical cannabis, there is a considerable gap in understanding due to federal restrictions.

The National Cannabis Study is designed to follow a representative cohort of approximately 10,000 patients, spanning from cannabis naivety to a year or more of marijuana use. Johannes Thrul, a mental health professor at the Johns Hopkins Bloomberg School of Public Health, explained that the assessments will be more frequent in the initial stages, acknowledging that patients are likely to experiment with different products to find what best addresses their symptoms.

While Johns Hopkins pursues this independent initiative, the National Institutes of Health (NIH) has expressed the need for a new Resource Center for Marijuana and Cannabinoid Research. The initiative aims to tackle the challenges and barriers hindering cannabis research. Numerous federal health agencies have prioritized overcoming these barriers due to the cumbersome and costly registration process scientists face when trying to access marijuana given its current Schedule I status under the Controlled Substances Act.

Significantly, the Drug Enforcement Administration (DEA) is actively reviewing the policy classifying marijuana as a Schedule I drug, prompted by a recommendation from the HHS to reclassify it to Schedule III. This potentially signals a shift in the regulatory landscape, opening avenues for more streamlined and accessible marijuana research.

Cannabis companies such as Green Thumb Industries Inc. (CSE: GTII) (OTCQX: GTBIF) are likely to await the findings of the study as those findings could provide valuable insights into the specific ways in which customers are benefiting from the medical marijuana products they buy.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

Astrotech Corp. (NASDAQ: ASTC) Announces New Mass Spectrometry Technology Application for Chemical Manufacturing and Introduces the Pro-Control Subsidiary

Astrotech’s newest subsidiary, Pro-Control, will use the company’s mass spectrometer technology to improve purity, and yields of distilled chemicals
Pro-Control delivers value by improving lost yields and delivering found profits directly to the bottom line with little, which the company believes will lead to an overall increase in profitability
Astrotech believes that the Pro-Control MVP has the ability to routinely improve yields from 20% to 30%
The company is introducing its proprietary ATi Mass Spectrometer Technology into the vast chemical manufacturing and process control markets

Astrotech (NASDAQ: ASTC), is an instrumentation company that is focused on commercializing its proprietary ATi Mass Spectrometer Technology(TM) that is now used in airports and agriculture applications throughout the world.

Astrotech continues to expand its ATi Mass Spectrometer Technology into new markets and has announced the introduction of its newest Pro-Control-1000(TM) product line of instrumentation designed to improve chemical manufacturing efficiencies. Astrotech is also announcing the creation of its newest wholly owned subsidiary, Pro-Control, Inc. that has been awarded an exclusive ATi field-of-use license for worldwide chemical manufacturing and process control applications.

The Pro-Control-1000(TM) mass-spec is ideally suited for use in the chemical manufacturing industry due to its rugged design and highly reliable chemical analysis.

The Pro-Control-1000(TM) is easy to operate with daily auto-calibration and auto-tune. The custom library feature makes it easy to create a unique chemical library. And the programable user interface adapts to every chemical manufacturing application and testing protocol.

The Pro-Control-1000(TM) product line includes two models:

The Pro-Control-1000-D1(TM) is a fully automated mass spectrometer that is configured to continually analyze the process gases while adjusting the PLC controls (temp, flow, pressure), for Maximum Value Processing (max purities and yields).
The Pro-Control-1000-D2(TM) is a manually prepared test that analyzes in-process liquids while providing graphical feedback needed to adjust the operating parameters (temp, flow, pressure) for maximum efficiency.

According to Mordor Intelligence, the global mass spectrometry market is estimated to reach $6.37 billion in 2023 and is expected to grow to $8.63 billion by 2028 at a CAGR of 6.25%. The market’s growth is being driven primarily by the technological advances in the mass spectrometer device market. The key market players are continuously working to advance existing products and launch innovative advanced mass spectrometer devices into various applications including chemical manufacturing (https://cnw.fm/DxoIo). Pro-Control is offering its proprietary mass-spec technology to customers that are interested in significantly improving the purity and yields and profits from the manufacturing of distilled chemical products.

Thomas Pickens, CEO and CTO of Astrotech said, “The company is very excited to be introducing our new Pro-Control, Inc. subsidiary along with the very capable Pro-Control-1000(TM) family of rugged mass-spectrometers. The ideal Pro-Control customer is a large-volume manufacturer of chemical products seeking to improve bottom line profits. We believe that Pro-Control MVP can routinely improve manufacturing yields from 10% to 30% and we are excited to introduce our technology to the vast chemical manufacturing market.”

For more information, visit the company’s website at www.AstrotechCorp.com.

NOTE TO INVESTORS: The latest news and updates relating to ASTC are available in the company’s newsroom at https://cnw.fm/ASTC

About CannabisNewsWire

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com